Medical Services

Essential thrombocythemia(ET) is a rare, chronic myeloproliferative neoplasm where the bone marrow produces excessive platelets. Platelets are important for proper blood clotting, but an overproduction of platelets might cause the danger of the formation of aberrant blood clots and unexpected bleeding. The disorder normally progresses slowly and is most commonly diagnosed in adults over 50 years of age, although it can afflict younger people.

Many persons with essential thrombocythemia are symptomless and discovered during normal blood tests. You may get headaches, dizziness, fatigue, visual abnormalities, numbness or tingling in the hands and feet, chest discomfort, or unexplained bruises. Serious consequences include stroke, heart attack, deep vein thrombosis, pulmonary embolism, or major bleeding events.

Genetic mutations, such as JAK2, CALR, or MPL, are typically connected with the condition, leading to unregulated platelet production. Diagnosis: Complete blood count, bone marrow examination, genetic mutation testing, and exclusion of alternative reasons for high platelet counts.

Treatment is to limit the risk of problems and may include low-dose aspirin, platelet-lowering drugs such as hydroxyurea or interferon, and regular monitoring. With suitable treatment and regular monitoring, most people with essential thrombocythemia can expect to lead a decent quality of life and have almost a normal life expectancy.